Advertisement

Topics

A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug (NSAID)-Associated Dyspepsia and Gastroduodenal Injury

2014-08-27 03:13:02 | BioPortfolio

Summary

The aim of this study is to determine whether rabeprazole is superior to placebo in preventing dyspepsia and gastroduodenal injury in subjects with osteoarthritis (OA) and/or rheumatoid arthritis (RA) and/or bone pain.

Description

Non steroidal anti-inflammatory drugs (NSAIDs) are well known to increase the risk of gastroduodenal (GD) ulcer and its complications. Up to 40% of average-risk NSAID users suffer from dyspepsia without endoscopic evidence of gastroduodenal injury. It results a significant loss of productivity and impairment of Quality of Life (QoL). Proton pump inhibitors (PPIs) have been shown to be effective in preventing and reducing NSAID-induced GD injury. PPIs are believed to have a class effect but Rabeprazole, the least expensive PPI, is grossly under-utilized in this area .

Current Hospital Authority (HA) guidelines, however, only endorse the use of PPI in patients at high risk of ulcer bleeding. Since NSAID-induced dyspepsia is not an indication for PPI according to HA guidelines, those patients do not receive PPI for treatment.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Osteoarthritis

Intervention

Rabeprazole, Rabeprazole Placebo

Location

Prince of Wales Hospital
Hong Kong
China

Status

Recruiting

Source

Chinese University of Hong Kong

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:13:02-0400

Clinical Trials [821 Associated Clinical Trials listed on BioPortfolio]

A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)

The purpose of this study is to assess pharmacokinetics of rabeprazole under postprandial condition.

Rabeprazole Protection of Aspirin Induced Gastric Damage.

To determine the effectiveness of rabeprazole in preventing or decreasing acute gastroduodenal injury caused by therapeutic doses of aspirin in a placebo-controlled, randomized, double-bli...

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers

The purpose of the study is to evaluate and compare the pharmacokinetics (blood levels) of 2 different formulations, assess the effect of food on the pharmacokinetics and assess safety of ...

A Study of E3810 for Japanese Subjects With Functional Dyspepsia

The purpose of this study is to assess the efficacy and safety of Rabeprazole compared to placebo in Japanese subjects with Functional Dyspepsia.

Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)

The purpose of this study is to determine the production of mucin in GERD/RE subjects before and after 8 weeks of treatment with rabeprazole.

PubMed Articles [1515 Associated PubMed Articles listed on BioPortfolio]

Therapy of GERD and FD overlap with symptoms after usual-dose PPI: acotiamide plus usual-dose PPI vs. double-dose PPI.

Gastroesophageal reflux disease (GERD) and functional dyspepsia (FD) often coexist or overlap. In this study, the efficacy of acotiamide in combination with a standard dose of rabeprazole for GERD and...

Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers.

Endoscopic submucosal dissection (ESD) is a well-established minimally invasive treatment for early gastric cancer. To heal ESD-induced ulcers, we commonly prescribe proton pump inhibitors (PPIs). Von...

Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury.

Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury-authors' reply.

A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - The HUMOR trial.

To assess the efficacy of adalimumab in patients with erosive hand osteoarthritis (OA).

Medical and Biotech [MESH] Definitions

A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.

Viscoelastic solutions that are injected into JOINTS in order to alleviate symptoms of joint-related disorders such as OSTEOARTHRITIS.

More From BioPortfolio on "A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug (NSAID)-Associated Dyspepsia and Gastroduodenal Injury"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...


Searches Linking to this Trial